Simulations Plus (NASDAQ:SLP) Now Covered by Analysts at KeyCorp

KeyCorp assumed coverage on shares of Simulations Plus (NASDAQ:SLP) in a report published on Monday, MarketBeat Ratings reports. The brokerage issued an overweight rating and a $47.00 price target on the technology company’s stock. KeyCorp also issued estimates for Simulations Plus’ Q4 2024 earnings at $0.05 EPS, FY2024 earnings at $0.54 EPS, Q1 2025 earnings at $0.09 EPS, Q2 2025 earnings at $0.19 EPS, Q3 2025 earnings at $0.20 EPS, Q4 2025 earnings at $0.14 EPS, FY2025 earnings at $0.63 EPS and FY2026 earnings at $0.76 EPS.

SLP has been the subject of a number of other research reports. Craig Hallum reaffirmed a buy rating and issued a $56.00 price target on shares of Simulations Plus in a report on Wednesday, July 3rd. Oppenheimer boosted their price objective on Simulations Plus from $55.00 to $65.00 and gave the stock an outperform rating in a research note on Thursday, June 13th. William Blair initiated coverage on Simulations Plus in a research note on Friday, June 28th. They set an outperform rating for the company. Finally, JMP Securities initiated coverage on Simulations Plus in a research note on Tuesday, July 16th. They set a market perform rating for the company. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat, the company presently has an average rating of Moderate Buy and a consensus target price of $56.00.

Simulations Plus Trading Down 2.1 %

NASDAQ SLP opened at $39.99 on Monday. The stock has a market capitalization of $800.20 million, a price-to-earnings ratio of 83.31 and a beta of 0.72. Simulations Plus has a twelve month low of $32.69 and a twelve month high of $52.69. The stock has a 50-day moving average of $44.48 and a 200 day moving average of $43.84.

Simulations Plus (NASDAQ:SLP) last released its quarterly earnings results on Tuesday, July 2nd. The technology company reported $0.19 earnings per share for the quarter, topping analysts’ consensus estimates of $0.15 by $0.04. The company had revenue of $18.54 million during the quarter, compared to analysts’ expectations of $17.92 million. Simulations Plus had a return on equity of 7.80% and a net margin of 14.36%. Simulations Plus’s quarterly revenue was up 14.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.20 EPS. Equities analysts predict that Simulations Plus will post 0.52 EPS for the current fiscal year.

Simulations Plus Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, August 5th. Stockholders of record on Monday, July 29th will be given a $0.06 dividend. The ex-dividend date is Monday, July 29th. This represents a $0.24 dividend on an annualized basis and a dividend yield of 0.60%. Simulations Plus’s dividend payout ratio (DPR) is presently 50.00%.

Insider Activity

In other news, Director Walter S. Woltosz sold 20,000 shares of the company’s stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $46.71, for a total value of $934,200.00. Following the completion of the sale, the director now directly owns 3,540,857 shares in the company, valued at $165,393,430.47. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, Director Walter S. Woltosz sold 20,000 shares of the company’s stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $46.71, for a total value of $934,200.00. Following the completion of the sale, the director now directly owns 3,540,857 shares in the company, valued at $165,393,430.47. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Daniel L. Weiner sold 750 shares of the company’s stock in a transaction that occurred on Friday, June 28th. The shares were sold at an average price of $49.32, for a total value of $36,990.00. Following the completion of the sale, the director now owns 7,009 shares of the company’s stock, valued at $345,683.88. The disclosure for this sale can be found here. Insiders sold 24,500 shares of company stock worth $1,153,198 over the last ninety days. Corporate insiders own 20.90% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in SLP. Conestoga Capital Advisors LLC grew its position in Simulations Plus by 12.5% in the fourth quarter. Conestoga Capital Advisors LLC now owns 2,259,176 shares of the technology company’s stock worth $101,098,000 after acquiring an additional 251,299 shares during the period. Ophir Asset Management Pty Ltd purchased a new position in Simulations Plus in the fourth quarter worth approximately $7,156,000. Silvercrest Asset Management Group LLC purchased a new position in Simulations Plus in the first quarter worth approximately $4,717,000. Wasatch Advisors LP grew its position in Simulations Plus by 36.5% in the first quarter. Wasatch Advisors LP now owns 381,693 shares of the technology company’s stock worth $15,707,000 after acquiring an additional 102,135 shares during the period. Finally, Congress Asset Management Co. MA grew its position in Simulations Plus by 34.6% in the first quarter. Congress Asset Management Co. MA now owns 171,490 shares of the technology company’s stock worth $7,057,000 after acquiring an additional 44,129 shares during the period. 78.08% of the stock is currently owned by hedge funds and other institutional investors.

About Simulations Plus

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.